Dare Bioscience vs Cartesian Therapeutics
Cartesian Therapeutics is the larger business, with $2.8m of revenue in fiscal 2025 against $1.0m for Dare Bioscience (2.7 times as much). Dare Bioscience grew faster (10429.4% against -92.8%). Dare Bioscience kept more of each dollar of sales as profit: a net margin of -1300.7% against -4658.6%.
| Latest fiscal year | Dare BioscienceDARE, 2025 | Cartesian TherapeuticsRNAC, 2025 |
|---|---|---|
| Revenue | $1.0m | $2.8m |
| Revenue growth | 10429.4% | -92.8% |
| Net income | −$13.4m | −$130m |
| Operating margin | -1315.5% | -5127.1% |
| Net margin | -1300.7% | -4658.6% |
| Return on equity | — | — |
| Free cash flow | −$10.3m | −$79.4m |
| Cash | $24.7m | $125m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 24 | 75 |
| Market value | $9.7m | $193m |
| Price vs our value range | — | — |
| Moat score | — | 9 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 3 sales |